Galantamine was effective in mild-to-moderate Alzheimer disease

September 2006
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p50
Academic Journal
The article discusses whether galantamine improve clinical outcomes in patients with mild-to-moderate Alzheimer disease. 30 patients with mild-to-moderate dementia were given galantamine, 8 mg/d for 4 weeks, followed by 16 mg/d for 4 weeks, then 16 to 24 mg/d for 8 weeks. It was found that galantamine improved clinical outcomes in patients with mild-to-moderate Alzheimer disease.


Related Articles

  • Exercise Plus Behavioral Management in Patients With Alzheimer Disease: A Randomized Controlled Trial. Teri, Linda; Gibbons, Laura E.; McCurry, Susan M.; Logsdon, Rebecca G.; Buchner, David M.; Barlow, William E.; Kukull, Walter A.; LaCroix, Andrea Z.; McCormick, Wayne; Larson, Eric B. // JAMA: Journal of the American Medical Association;10/15/2003, Vol. 290 Issue 15, p2015 

    Context: Exercise training for patients with Alzheimer disease combined with teaching caregivers how to manage behavioral problems may help decrease the frailty and behavioral impairment that are often prevalent in patients with Alzheimer disease. Objective: To determine whether a home-based...

  • Treatment slows moderate to severe Alzheimer's disease. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);4/12/2003, Vol. 326 Issue 7393, p784 

    Reports that a treatment has been shown to slow the mental and physical decline of patients with moderate to severe Alzheimer's disease. How researchers in the United States conducted a double blind, randomized controlled trial of the drug memantine; Review of memantine by the U.S. Food and...

  • Ginkgo biloba for dementia. Stevermer, James J.; Lindbloom, Erik J. // Journal of Family Practice;Jan1998, Vol. 46 Issue 1, p20 

    The article presents a study, which assessed the safety and efficacy of Ginkgo biloba or EGb 761 in patients with dementia. Ginkgo biloba is used in Europe to alleviate symptoms from chronic neurological diseases. It is one of the most commonly prescribed medications in Germany. Three hundred...

  • Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial. Kessler, Holger; Pajonk, Frank-Gerald; Bach, Daniela; Schneider-Axmann, Thomas; Falkai, Peter; Herrmann, Wolfgang; Multhaup, Gerd; Wiltfang, Jens; Schäfer, Stephanie; Wirths, Oliver; Bayer, Thomas // Journal of Neural Transmission;Dec2008, Vol. 115 Issue 12, p1651 

    A plethora of reports suggest that copper (Cu) homeostasis is disturbed in Alzheimer’s disease (AD). In the present report we evaluated the efficacy of oral Cu supplementation on CSF biomarkers for AD. In a prospective, randomized, double-blind, placebo-controlled phase 2 clinical trial...

  • Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer's Disease. Kavanagh, S.; Howe, I.; Brashear, H.R.; Wang, D.; Van Baelen, B.; Todd, M.; Schwalen, S. // Current Alzheimer Research;Mar2011, Vol. 8 Issue 2, p175 

    No abstract available.

  • Donepezil was no better than placebo for agitation in patients with Alzheimer disease. Van Reekum, Robert // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p7 

    The article focuses on the randomized placebo-controlled trial investigating if Donepezil is better than placebo for clinically significant agitation that has not responded to psychosocial treatment in patients with Alzheimer disease. The trial, conducted with 259 patients (39 years of age),...

  • Does Solanezumab Modify Alzheimer's Disease Progression? Remaly, Jake // Neurology Reviews;Sep2015, Vol. 23 Issue 9, p20 

    The article discusses an analysis of data from 2 completed phase 3 trials, EXPEDITION and EXPEDITION2 and an ongoing open-label extension EXPEDITION-EXT to assess the effect of solanezumab in patients with mild Alzheimer's disease dementia. It points out that the efficacy of solanezumab...

  • Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy. Kobak, K. A. // Current Alzheimer Research;Oct2010, Vol. 7 Issue 7, p637 

    No abstract available.

  • Nutrition and prevention of Alzheimer's dementia. Swaminathan, Arun; Jicha, Gregory A. // Frontiers in Aging Neuroscience;Oct2014, Vol. 6, p1 

    A nutritional approach to prevent, slow, or halt the progression of disease is a promising strategy that has been widely investigated. Much epidemiologic data suggests that nutritional intake may influence the development and progression of Alzheimer's dementia (AD). Modifiable, environmental...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics